1. Home
  2. VSTS vs DBVT Comparison

VSTS vs DBVT Comparison

Compare VSTS & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vestis Corporation

VSTS

Vestis Corporation

HOLD

Current Price

$9.25

Market Cap

1.0B

Sector

N/A

ML Signal

HOLD

DBVT

DBV Technologies S.A.

HOLD

Current Price

$21.33

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VSTS
DBVT
Founded
1936
2002
Country
United States
France
Employees
N/A
90
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.1B
IPO Year
2023
2014

Fundamental Metrics

Financial Performance
Metric
VSTS
DBVT
Price
$9.25
$21.33
Analyst Decision
Sell
Buy
Analyst Count
4
7
Target Price
$5.88
$32.04
AVG Volume (30 Days)
997.5K
231.3K
Earning Date
05-05-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
10.26
EPS
N/A
N/A
Revenue
$2,734,839,000.00
$5,636,000.00
Revenue This Year
N/A
$79.21
Revenue Next Year
$1.67
$1,754.26
P/E Ratio
N/A
N/A
Revenue Growth
N/A
35.77
52 Week Low
$3.98
$7.53
52 Week High
$9.80
$26.19

Technical Indicators

Market Signals
Indicator
VSTS
DBVT
Relative Strength Index (RSI) 75.88 51.95
Support Level $7.24 $19.64
Resistance Level $9.80 $21.84
Average True Range (ATR) 0.32 1.21
MACD 0.15 0.17
Stochastic Oscillator 97.47 54.34

Price Performance

Historical Comparison
VSTS
DBVT

About VSTS Vestis Corporation

Vestis Corp is a provider of uniform rentals and workplace supplies across the United States and Canada. It provides uniforms, mats, towels, linens, restroom supplies, first-aid supplies, safety products, and other workplace supplies. The Company serves customers ranging from small, family-owned operations with a single location to large corporations and national franchises with multiple locations. The company operates in the United States and Canada as reportable segments. The company earns the majority of its revenue from the United States.

About DBVT DBV Technologies S.A.

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.

Share on Social Networks: